Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells

Gene Therapy

Volumn 7, Issue 3, 2000, Pages 241-248

  Suzuki, T ^a   Anderegg, B ^b   Ohkawa, T ^a   Irie, A ^a   Engebraaten, O ^a   Halks Miller, M ^a   Holm, P S ^c   Curiel, D T ^c   Kashani Sabet, M ^b   Scanlon, K J ^a  

^a BAYER AG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

BT 474; Gene therapy; HER 2 neu; Recombinant adenovirus; Ribozymes

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; RIBOZYME; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; FEMALE; GENE THERAPY; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 0033993508     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301065     Document Type: Article

References (39)

1. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1980; 319: 226-230.
2. Yamamoto T et al. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature 1986; 319 230-234.
3. Di Fiore PP et al. Overexpression of the human EGF receptor confers an EGF-dependent transformed to NIH 3T3 cells. Cell 1987; 51: 1063-1070.
4. HER2 causes transform-ation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 1987; 84: 7159-7163.
5. Di Fiore PP et al. erbB-2 is a potent oncogene when overexpressed in NIH 3T3 cells. Science 1987; 237: 178-182.
6. Lonardo F et al. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. New Bio 1990; 2: 992-1003.
7. Gusterson BA. Identification and interpretation of epidermal growth factor and c-erbB-2 overexpression. Eur J Cancer 1992; 28: 263-267.
8. Slamon DJ et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1980; 244: 707-712.
9. Slamon DJ et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
10. Perren TJ. c-erbB-2 oncogene as a prognostic marker in breast cancer (editorial). Br J Cancer 1991; 63: 328-332.
11. Gullick WJ et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991; 63: 434-138.
12. Muss HB et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. New Engl J Med 1994; 330: 1260-1266.
13. Pier GN et al. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 1990; 45: 457-461.
14. Press MF, Cordon-Cardo C, Slamon D. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990; 5: 953-962.
15. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitized human breast cancer cells to tumor necrosis factor. Mol Cell Biol 1989; 9: 1165-1172.
16. Fendly BM et al. The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer. Cancer Res 1990; 50: 1550-1558.
17. HER2 monoclonal antibodies. Cancer Immunol Immunother 1993; 37: 258-263.
18. Valone FH et al. Phase 1a/1b trial of bispecific antibody MDx-210 in patients with advanced breast or ovarian cancer that overexpress the proto-oncogene HER-2/neu. J Clin Oncol 1995; 13: 2281-2292.
19. Beerli RR, Wels W, Hynes NE. Intracellular expression of single chain antibodies reverts erb-B2 transformation. J Biol Chem 1994; 269: 23931-23936.
20. Deshane J et al. Intracellular single-chain antibody directed against erbB2 down-regulated cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Therapy 1994; 1: 332-337.
21. Deshane J et al. Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis. Cancer Gene Ther 1996; 3: 89-98.
22. Deshane J et al. Targeted tumor killing via an intracellular antibody against erbB-2. J Clin Invest 1995; 96: 2980-2989.
23. Ebbinghaus SW et al. Triplex formation inhibits HER-2/neu transcription in vitro. J Clin Invest 1993; 92: 2433-2439.
24. Noonberb SB et al. Inhibition of transcription factor binding to the HER2 promoter by triplex-forming oligodeoxyribonucleotides. Gene 1994; 149: 123-126.
25. Vaughm JP et al. Antisense DNA downregulation of the erbB2 oncogene measured by a flow cytometrick assay. Proc Natl Acad Sci USA 1995; 92: 8338-8342.
26. Wiechen K, Dietel M. c-erbB-2 antisense phosphorothioate oligodeoxynucleotides inhibit growth and serum-induced cell spreading of p185c-erbB-2 overexpressing ovarian carcinoma cells. Intl J Cancer 1995; 63: 604-608.
27. Liu X, Pgo B. Inhibition of erbB-2 antisense oligonucleotides. Antisense Res Dev 1996; 6: 9-16.
28. Kashani-Sabet M, Scanlon KJ. Application of ribozymes to cancer gene therapy. Cancer Gene Ther 1995; 2: 213-223.
29. Kashani-Sabet M et al. Reversal of the malignant phenotype by an anti-ras ribozyme. Antisense Res Dev 1992; 2: 3-15.
30. Feng M et al. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res 1995; 55: 2024-2028.
31. Ohta Y, Kijima H, Kashani-Sabet M, Scanlon KJ. Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes. J Invest Derm 1996; 106: 275-280.
32. Ohta Y et al. Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells. Nucleic Acids Res 1996; 24: 938-942.
33. Kashani-Sabet M et al. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res 1994; 54: 900-902.
34. Funato T et al. Suppression of H-ras-mediated transformation in HIH3T3 cells by a ras ribozyme. Biochem Pharmacol 1994; 48: 1471-1475.
35. Czubayko F et al. Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation. Gene Therapy 1997; 4: 943-949.
36. Juhl H, Downing SG, Wellstein A, Czubayko F. HER-2/neu is rate-limiting for ovarian cancer growth. J Biol Chem 1997; 272: 29482-29486.
37. Wiechen K, Zimmer C, Dietel M. Selection of a high activity c-erbB-2 ribozyme using a fusion gene of c-erbB-2 and the enhanced green fluorescent protein. Cancer Gene Ther 1998; 5: 45-51.
38. Anderegg B, Horstmann M, Ernst M, Kabisch H. Transcription of tal-1, a putative oncogene playing an important role in childhood T-ALL, can be shown in normal peripheral blood cells by a highly sensitive RT-PCR assay. Pediatr Hematol Oncol 1997; 14: 349-358.
39. Nakajima-Lijima S, Hamada H, Reddy P, Takanuga TS. Molecular structure of the human cytooplasmic β-actin gene: intraspecies homology of sequences in the introns. Proc Natl Acad Sci USA 1985; 82: 6133-6137.